WINNIPEG, MANITOBA -- (MARKET WIRE) -- February 05, 2007 -- Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products is pleased to announce that it has successfully confirmed six protein biomarkers in its validation study for colorectal cancer.
